Julius Knowles, Partner at Partners Innovation Fund. Jay is a business development professional with more than 20 years in the industry and has helped to guide multiple early stage companies through drug discovery and development. He was previously CEO of X-BODY Biosciences (sold to Juno), a biologics platform company focused on generating fully-human antibodies. Prior to this, he was Head, Platforms, Strategic Alliances for Novartis, where he led a team responsible for creating technology-based and drug discovery collaborations, forging a number of major strategic alliances with biotech companies. Jay was also President of Novalar Pharmaceuticals, a specialty pharmaceutical company that brought a drug from idea stage through the clinic and onto the market. He was also Vice President, Business Development, at Novacea and at Structural Genomix, and Director, Research and Development Planning at Vertex Pharmaceuticals. He has an MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He is a Member of the Board of Directors at Aurigene, and represents the fund on the boards of Abcuro, Keros, and Tilos Therapeutics, and as a board observer at LTI, Quartet Medicine, and RaNA Therapeutics.
Dr. Carole Nuechterlein, Head of Roche Venture Fund. Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStatin Fremont California where she was General Counsel.
Carole currently serves on the board of LTI and as a board observer at Alios, Ambrx and Epic. She led the investments on Ambit, BioFire Diagnostics, Conatus, Envoy, Nereus & Pharmasset and served as a board observer for all of these except Pharmasset.
More information on the Roche Venture Fund can be found at www.venturefund.roche.com.
Clay Thorp, General Partner at Hatteras Venture Partners. Clay Thorp is an entrepreneur turned venture capitalist. Since 1995, Clay has co-founded seven companies in the life science arena and co-founded Hatteras in 2001. Since co-founding Hatteras, Clay has been instrumental in building the firm and has led investments in a range of life science companies, including biopharmaceutical, medical device, diagnostics, and research informatics.
Clay was the lead investor and led the strategic transaction process for ArtusLabs that resulted in its sale to PerkinElmer in 2011. He was a co-founder and served as CEO and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired in April 2005 by Symyx Technologies (SMMX). Clay is a co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc. He was the co-founder and head of corporate development for Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio in May of 2000. Prior to Novalon, Clay was the co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins.
Clay currently serves as Chairman of GeneCentric Diagnostics and Lead Director of Pathfinder Therapeutics. He is also on the boards of PhaseBio Pharmaceuticals, Clearside Biomedical, and G1 Therapeutics. He holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and history from the University of North Carolina at Chapel Hill. Community and Board Engagements: Clay started his career as a social entrepreneur by co-founding the Student Coalition for Action in Literacy Education (SCALE) as a junior at UNC-Chapel Hill in 1989. For that, he was honored as Point of Light by George H.W. Bush. Since that time, Clay has been active at state and national levels in public policy and public service. He is a past board member of the NC Biotechnology Center, CED, Public Allies, and the Wildacres Leadership Initiative. He currently serves on the Board of Trustees of the NC Supplemental Retirement System and the NC BioFuels Center. Clay is also a member of the Foundation Board of the NC School of Science and Mathematics.
Steven E. Hall, Ph.D., Venture Partner at Lilly Ventures. Steve Hall, Ph.D., is currently a Venture Partner at Lilly Ventures, following more than 25 years of drug discovery experience at both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures in 2009, Steve was Senior Vice President, Research and Development, at Serenex, Inc. which was acquired by Pfizer in April 2008. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. Steve started his career in 1982 at the Squibb Institute for Medical Research as a medicinal chemist where he was involved with multiple projects in cardiovascular disease and inflammation.
Steve is an author/co-author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology. Steve serves as CEO of Esanex, Inc. and sits on the boards of Cerulean Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, InnoCentive, Lysosomal Therapeutics, Numerate, Nimbus Discovery, and is a board observer at Viamet.
Bernard Davitian, Vice President and Managing Director at Sanofi-Genzyme BioVentures. Bernard Davitian has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. His track record includes, among others, the successful IPO of Transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction.
Bernard joined Sanofi in 2010 as Vice President, Deputy of Global Head, Business Development Corporate Licenses and was promoted to Vice President and Managing Director of SGBV in 2012. Prior to Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech Pharmaceuticals, and EVP & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO.
In addition to his SGBV-related Boards of Directors responsibilities, which include Immune Design, Proteostasis Therapeutics, Esperance Pharmaceuticals and Kahr Medical, Bernard also represents Sanofi on the Board of Directors of Warp Drive Bio.
Bernard holds an MSc in Management from EM Lyon Business School (France). He is also a Certified Public Accountant (CPA) and holds an executive M.B.A. (AMP program) from Wharton Business School.
Bruce Booth, Ph.D., Partner at Atlas Venture. Bruce Booth, Ph.D., is a partner in the life sciences group and focuses on the discovery and development of novel therapeutics.
Since joining Atlas in 2005, Bruce has been involved in the founding and funding a number of innovative companies with a particular focus on capital efficient models for drug R&D. He currently serves on the board of miRagen Therapeutics (co-founder), Zafgen, Bicycle Therapeutics, Nimbus Discovery (co-founder), Rodin Therapeutics (co-founder), and several other seed-stage biotech companies. Previously, Bruce served on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences), among others.
Prior to joining Atlas in 2005, Bruce was an investor with Caxton Health Holdings and before that, a consultant at McKinsey & Company, a global strategic management consulting firm. While at McKinsey, he worked extensively with pharmaceutical and biotechnology firms to address R&D productivity issues, as well as portfolio management, new product commercialization, and business development.
Bruce currently serves on UCB Pharma’s Scientific Advisory Board, as well as Pfizer’s Healthcare “R&D 2020″ Innovation Think Tank, and participates on several other advisory boards for pharmaceutical companies and academic medical centers. Bruce is also a trustee of the New York Academy of Medicine. He recently joined the Science Exchange’s Reproducibility Initiative Advisory Board, focused on improving the reliability of translational research.
Bruce writes about life science venture capital topics at his blog LifeSciVC.com, which is also syndicated with Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. In 2010, Bruce was named to Boston Business Journal’s “40 under 40” list.
As a British Marshall Scholar, Bruce received a D.Phil. (Ph.D.) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Kees Been, Founder, President and CEO of LTI. Kees Been was formerly the President and CEO of EnVivo Pharmaceuticals where he ledEnVivo for eight years from an early-stage start-up to a respected CNS company with a broad pipeline of NCE drug compounds, its lead compound in a phase 3 program for Alzheimer’s disease and schizophrenia. He spent four years at Biogen where he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development.
Bob Carpenter, Founder of LTI and Chairman of the Board. Bob Carpenter is a successful entrepreneur, having founded and lead several companies, such as VacTex Inc. (acquired by Aquila Biopharmaceuticals in 1998), and GelTex Pharmaceuticals and Integrated Genetics, both merged with Genzyme. Following the merger of IG, Bob was EVP, CEO and chairman of Genzyme’s subsidiary IG Laboratories till 1991, and served as a Director on Genzyme’s Board until its acquisition. He’s currently Chairman of Hydra Biosciences.